AGENDA

POETIC Winter Meeting
February 28th – March 1st, 2019
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah

WEDNESDAY, FEBRUARY 27

**EVENING SESSION**
4:00 PM MT (6:00 PM EST)  
Huntsman Cancer Institute Research South, 6th Floor Conference Room

**4:00 PM MT (6:00 EST) BOARD OF DIRECTORS MEETING (Closed Session)**

**5:00 PM DISSERTER**
Board of Directors

THURSDAY, FEBRUARY 28

**MORNING SESSION**
7:30 AM – 1:15 PM  
Huntsman Cancer Institute Research South, 1st Floor 
J Willard and Alice S Marriott Foundation Auditorium

**7:15 – 10:15 AM**
Shuttle bus service: University Guest House to HCI

**7:30 – 8:00 AM**
REGISTRATION/BREAKFAST

**GREETINGS/INTRODUCTIONS**
Nellie Ulrich, PhD, Jon M. and Karen Huntsman Presidential Professor in Cancer Research, Director Comprehensive Cancer Center at Huntsman Cancer Institute, Professor, Department of Population Health Sciences, University of Utah
Richard Lemons, MD, PhD, Division Chief and Medical Director, University of Utah, Huntsman Cancer Institute
Luke Maese, DO, University of Utah, Huntsman Cancer Institute

**WELCOME ADDRESS**
Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center, Co-Founder and Co-Director, POETIC
Norman Lacayo, MD, Lucile Packard/Stanford University, Co-Director, POETIC

**8:00 – 8:15 AM**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 – 10:30 AM</td>
<td><strong>KEYNOTE ADDRESS</strong></td>
</tr>
<tr>
<td>8:15 – 9:15 AM</td>
<td><strong>Title TBD</strong>&lt;br&gt;Kevin Jones, MD, Associate Professor of Orthopedics, Huntsman Institute, University of Utah</td>
</tr>
<tr>
<td>9:15 – 10:15 AM</td>
<td><strong>Targeting therapeutic vulnerabilities in RAS-driven cancers</strong>&lt;br&gt;Martin McMahon, PhD, Cumming-Presidential Professor of Cancer Biology, Dept. of Dermatology &amp; Senior Director for Preclinical Translation, Huntsman Cancer Institute, University of Utah</td>
</tr>
<tr>
<td>10:15 – 10:30 AM</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>10:30 AM – 11:00 AM</td>
<td><strong>TREEHOUSE CHILDHOOD CANCER INITIATIVE</strong>&lt;br&gt;Comparative RNA sequencing analysis for identification of cancer driver pathways in childhood cancers&lt;br&gt;Lauren M. Sanders, BA, PhD student, UC Santa Cruz, Human Genomics Institute</td>
</tr>
<tr>
<td>11:05 AM – 11:45 AM</td>
<td><strong>DRUG-NEM APPROACH</strong>&lt;br&gt;Identifying the Optimal Drug Combinations for the Individual Patient by Accounting for Intratumoral Heterogeneity with Single Cell Resolution&lt;br&gt;Sylvia Pleveritis, PhD, Stanford University (Via Webex)</td>
</tr>
<tr>
<td>11:45 AM – 12:15 PM</td>
<td><strong>TOUR OF HUNTSMAN CANCER INSTITUTE</strong></td>
</tr>
<tr>
<td>12:15 – 1:15 PM</td>
<td><strong>LUNCH – POINT</strong></td>
</tr>
<tr>
<td><strong>AFTERNOON SESSION</strong></td>
<td>Huntsman Cancer Institute Research South, 1st Floor&lt;br&gt;J Willard and Alice S Marriott Foundation Auditorium</td>
</tr>
<tr>
<td>1:15 – 5:00 PM</td>
<td><strong>iMATRIX Trials: Clinical update</strong>&lt;br&gt;Stephen Simko, MD, Medical Director&lt;br&gt;Innovative Pediatric Oncology Drug Development, Genentech</td>
</tr>
<tr>
<td>1:15 – 2:15 PM</td>
<td><strong>Pre-clinical/Clinical development of PV-10 and an Upcoming Clinical Trial in Pediatric Solid tumors</strong>&lt;br&gt;Eric Wachter, PhD, Chief Technology Officer Provectus Biopharmaceuticals, Inc.&lt;br&gt;Aru Narendran, MD, PhD, Alberta Children’s Hospital&lt;br&gt;Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>2:15 – 3:15 PM</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>3:15 – 3:30 PM</td>
<td><strong>PEDIATRIC CANCER THERAPEUTIC MODELING</strong></td>
</tr>
<tr>
<td>3:30 – 4:45 PM</td>
<td><strong>Exosomal Delivery of PV-10</strong>&lt;br&gt;David Lyden, MD, PhD, Weill Cornell Medical Center</td>
</tr>
<tr>
<td>3:30 – 4:15 PM</td>
<td><strong>Comparative Oncology – Ablation model using PV10 in Dogs with Metastatic Lung Cancer</strong>&lt;br&gt;Todd Heaton, MD, Memorial Sloan Kettering Cancer Center&lt;br&gt;Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</td>
</tr>
</tbody>
</table>
4:45 – 5:00 PM
TRANSITION UPDATE
Oby Nwankwo, DrPH, POETIC Research Project Manager, Clinical Research Administration, MSKCC
Mary Warren, Director, Clinical Research Multi-Site Compliance, Clinical Research Administration, MSKCC

5:00 – 5:15 PM
COMMON RULE UPDATE
Tanya Trippett, MD, Co-Founder and Director POETIC
Norman Lacayo, MD, Director, POETIC

5:15 PM
MEETING ADJOURN
Shuttle bus service: HCI to University Guest House

7:00 PM
DINNER – STANZA ITALIAN BISTRO AND WINE BAR

6:45 – 10:00 PM
Shuttle bus service: University Guest House to Stanza; Stanza to University Guest House

FRIDAY, MARCH 1

MORNING SESSION
8:00 AM – 1:15 PM
Huntsman Cancer Institute Research South, 1st Floor
J Willard and Alice S Marriott Foundation Auditorium

7:45 – 10:45 AM
8:00 – 9:00 AM
REGISTRATION/BREAKFAST

8:00 – 8:40 AM
PI Meeting (Closed Session) Location HCI South 1A
PIS only

9:00 – 10:00 AM
POETIC TRANSLATIONAL GENOMICS PROGRAM
David Lyden, MD, PhD, Weill Cornell Medical Center
Olga Kovalchuk, MD, PhD, University of Lethbridge
Bodour Salhia, PhD, University of Southern California

10:00 – 10:30 AM
Multi-Parallel Molecular and Immunologic Profiling in Relapsed/Refractory Pediatric Tumors – A Multicenter POETIC Biology Study
Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center
Norman Lacayo, MD, Lucile Packard Children’s Hospital

10:30 – 10:45 AM
BREAK

10:45 – 11:15 AM
ACTIVE POETIC TRIALS

10:45 – 11:00 AM
Phase I Study of Carfilzomib, Cyclophosphamide, Etoposide
PI: Jessica Boklan, MD, Phoenix Children’s Hospital

11:00 – 11:15 AM
Phase I/II Trial of Neratinib in Pediatric Malignancies (Closed Session)
PI: Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
</table>
| 11:15 AM – 12:15 PM | **Neoantigen Vaccines for Refractory Childhood Leukemia**  
**Project Plan & Preliminary Data**  
Aru Narendran, MD, PhD, Alberta Children’s Hospital | | |
| 12:15 – 1:15 PM | **LUNCH**                                      |                                                 | |
| 12:15 – 1:15 PM | **INTERNATIONAL INITIATIVE: INTERNATIONAL CHILDREN’S CANCER RESEARCH CENTRE IN GHANA**  
Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center | | |
| **AFTERNOON SESSION**  
1:15 – 4:00 PM | Huntsman Cancer Institute Research South, 1st Floor  
J Willard and Alice S Marriott Foundation Auditorium | | |
| 1:15 – 2:00 PM | **NEUROONCOLOGY INITIATIVES/CONCEPTS**          |                                                 | |
| 1:15 – 1:30 PM | **Overview of DIPG Subtypes and Pre-Clinical Plan for the ACVR1 Inhibitor**  
Cynthia Wetmore, MD, PhD, Phoenix Children’s Cancer Center | | |
| 1:30 – 1:45 PM | **Concept for Cobi/Plexiform Neurofibromas**  
Amy Smith, MD, Orlando Health | | |
| 1:45 – 2:00 PM | **A Phase I Trial of Loco-regional Infusion of 5’Azacytidine and Oral Vorinostat in Recurrent/Refractory Hypermethylated Pediatric Brain Tumors**  
Soumen Khatua, MD, MD Anderson Cancer Center | | |
| 2:00 – 2:15 PM | **BREAK**                                     |                                                 | |
| 2:15 – 3:15 PM | **Amgen Pipeline Presentation**               |                                                 | |
| | Anjali Sharma, MD, Medical Director, Clinical Development, Hematology-Oncology  
PK Morrow, Head, MCL-1 Program  
Greg Friberg, VP, R&D  
Lisa Bollinger, VP, Material Health and Pediatric Safety & Regulatory Affairs  
Eric Ng, Director, Pediatric Safety & Regulatory Affairs  
Tony Wagner, Director, Advocacy Amgen, Inc. | | |
| 3:15 – 3:45 PM | **OUTTAKE**                                   |                                                 | |
| | Tanya Trippett, MD, Co-Founder and Director POETIC  
Norman Lacayo, MD, Director, POETIC | | |
| 3:45 PM | **ADJOURN**                                   |                                                 | |
| 2:00 – 5:00 PM | **Shuttle bus service: HCI to University Guest House** | | |